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Abstract
Background: A pilot cardiovascular disease prevention project was implemented in the inner-city
West Midlands. It was evaluated by comparing its effectiveness to a control group where full
implementation was delayed by a year.
Methods: Cardiovascular risk factor data were extracted on all untreated patients 35 to 74 years
old from electronic medical databases in six general practices. A best estimate of ten-year CVD
risk cardiovascular risk was calculated on all patients using the extracted risk factor data. Default
risk-factor values were used for all missing risk factor data. High risk patients were thus identified.
In four practices a project nurse systematically invited, assessed and referred high risk patients for
treatment. Two control practices were provided with a list of their high risk patients. The
outcomes were the proportions of untreated high-risk patients who were assessed, identified as
eligible for treatment and treated under two strategies for identifying and treating such patients in
primary care.
Results: Of all high-risk patients suitable for inclusion in the project, 40.6% (95% CI: 36.7 to 45.7%)
of patients in intervention practices were started on treatment were started on at least one
treatment, compared to 12.7% (95% CI: 9.8% to 16.1%) in control practices.
Conclusion: A strategy using electronic primary care records to identify high risk patients for
CVD prevention works best with a process for acting on information, ensuring patients are invited,
assessed and treated.
Background
Current clinical guidelines largely use individuals' esti-
mated ten-year risk of developing cardiovascular disease
(CVD) to determine eligibility for treatment [1]. Risk of
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CVD is derived using the Framingham CVD risk equation
[2]. This requires data on the patient's age, gender, dia-
betic status, whether they have CVD, smoking status,
blood pressure, total and HDL cholesterol levels. Any
individual whose risk of developing CVD within the next
10 years exceeds 20% is eligible for treatment.
Patients with existing CVD are the highest priority in any
prevention programme. In the UK, general practices are
responsible for the primary health care needs of a regis-
tered population of patients. General practices are offered
incentives to identify and treat these patients in the Qual-
ity and Outcomes Framework of the Department of
Health [3]. Prevention in those without CVD but at high
risk of developing CVD was a priority in the National
Service Framework for Coronary Heart Disease, but is not
specifically covered under current incentives [4]. This
pilot therefore focused only on CVD primary prevention.
CVD prevention in those without existing CVD requires
identification of patients eligible for treatment and subse-
quent treatment. Usual current practice is to assess
patients' risk factors opportunistically. In many cases risk
factor data (such as age, sex, diabetic status, smoking his-
tory and blood pressure) are already recorded in practice
databases. This information could be used to prioritise
patients for CVD risk factor assessment [5].
Sandwell is a deprived urban area in the West Midlands of
England, 20.3% of the population are from minority eth-
nic groups (14.0% South Asian and 3.8% Afro-Carib-
bean) [6]. From 2003 to 2005 the standardised mortality
rates for coronary heart disease were 138 in males and 165
in females under 75 and for stroke 177 and 156 [7].
This paper reports the evaluation of a pilot CVD preven-
tion project in Sandwell. The project was implemented in
a stepped manner (in effect as a controlled trial) in order
to evaluate the effectiveness of the project. In the interven-
tion group, patients without existing CVD and not cur-
rently on antihypertensive treatment, were identified
from electronic primary care records. From these
untreated patients were identified those patients likely to
be at high risk of CVD. High risk patients were invited for
CVD risk factor assessment by a project nurse, assessed by
the project nurse and if they were found to be eligible for
treatment they were referred to the GP for prescription of
drug treatments. In the control group, full implementa-
tion was delayed for a year. At the start of the year
untreated patients likely to be at high risk of CVD were
identified in a similar manner to the intervention group.
The practices responsible for these patients were provided
with information identifying these patients as likely to be
at high-risk but made their own arrangements for assess-
ment and treatment. It was believed that the project
would increase the proportion of high risk patients
assessed and therefore increase the proportion of eligible
patients started on treatment. The intervention (system-
atic invitation by the project nurse) was extended to the
control group one year after the start of the project.
Methods
Population under study
The primary care trust identified general practices in Sand-
well Primary Care Trust (PCT) located in areas of the PCT
with the highest standardised mortality rates for CVD. To
facilitate data extraction, only practices that used Torex
electronic medical records databases were included. Par-
ticipating practices agreed to assess the patients identified
by the search strategy as probably at high risk and to fol-
low the local protocol for prescribing preventive treat-
ments. (Table 1) Six practices took part in the project.
Four smaller practices were selected as the intervention
group and two larger practices were selected as the control
group. The intervention group practices consisted of three
single partner practices and a nurse practitioner partner-
ship; the control group practices each had two partners.
The project was registered for research governance with
Sandwell Primary Care Trust, who determined that since
this was an evaluation of organisational change aimed to
Table 1: Sandwell Primary Care Trust's local protocol for prevention of CVD in primary care
Intervention Treatment eligibility criteria
Aspirin 75 mg Age ≥50 and calculated risk ≥20%
Antihypertensive treatment: Blood pressure ≥160/100 mm Hg
1. Bendroflumethiazide 2.5 mg
2. Lisinopril 5 mg Blood pressure ≥140/90 mm Hg calculated ten-year CVD risk ≥20%
3. Bisoprolol 10 mg
Simvastatin 40 mg Total cholesterol ≥7 mmol/l
Diabetic: age ≥40
Diabetic: total cholesterol ≥6 mmol/l
Any cholesterol level calculated ten-year CVD risk ≥20%BMC Public Health 2008, 8:73 http://www.biomedcentral.com/1471-2458/8/73
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improve access to freely available health services, formal
ethics committee approval was not required.
Data extraction
Patients were eligible for inclusion in the prevention
project if they were aged 35 to 74, did not have an existing
diagnosis of CVD and were not currently receiving a pre-
scription for antihypertensive treatment. A software query
compatible with Torex databases was written to identify
these patients and to extract their CVD risk factor data.
The extracted data included age, sex, diabetic status, smok-
ing status, the most recent three blood pressures extracted
within the last three years, the most recent total choles-
terol and HDL cholesterol levels within the last three years
and the practice's own patient identifier (a patient
number known only to the practice). Five practices were
visited and had data extracted in July 2005 and in one
practice in February 2006.
Determining risk and prioritising patients for assessment
In each of the six practices, extracted CVD risk factor data
were downloaded into an Excel spreadsheet and an esti-
mated CVD risk was calculated for all the included
patients using the Framingham risk equation [8]. Where
more than one blood pressure or cholesterol measure-
ment was available, the average of all the available meas-
urements was used to calculate risk. Where a risk factor
was not known, a default (or prior estimate) of the risk
factor status was used instead. In other words, CVD risk
was calculated using whatever risk factor information was
available on patients. In most cases this information was
incomplete because of missing cholesterol levels, blood
pressures or smoking status. This approach follows a pre-
viously described method [9,10].
The spreadsheet of CVD risks was returned to the practice
and then matched to the practice patients. In the Excel
spreadsheet patients were ranked from top to bottom in
descending order of CVD risk. In all six practices, probable
high-risk patients (patients whose ten-year CVD risk
exceeded 20%) were identified, the list was explained to
practice staff and the names were checked by practice staff
to exclude patients who had died, had illnesses that made
them unsuitable for CVD risk screening (e.g. terminally
ill) or had moved away.
Identification, assessment and treatment: intervention 
group
In the four intervention practices the project nurse under-
took a strategy of active invitation and assessment of
patients. Patients identified as probably at high-risk of
CVD were mailed an appointment to attend a CVD assess-
ment clinic in their practice. Patients who did not either
attend or reschedule their appointment were sent a sec-
ond and a third letter or telephoned (if a telephone
number was available). When patients attended, the
project nurse determined ethnicity, assessed lifestyle risk
factors including smoking history, drinking habit, waist
and hip measurement and ratio, weight and height and
body mass index; family history of CVD and measured
blood pressure and pulse. A fasting blood test was
arranged including renal and liver function tests, fasting
lipids and fasting glucose. The project nurse calculated
CVD risk, determined eligibility for drug treatments and if
appropriate discussed the potential benefits of treatment
using a risk and benefit calculator [11]. Eligible patients
were referred to the GP for prescription of drug treat-
ments. Appropriate patients were referred to smoking ces-
sation services, for exercise on prescription or for dietary
advice. Outcomes were assessed one year after the inter-
vention began. Patients
Identification, assessment and treatment: control group
In the two control practices, the practice took responsibil-
ity for arranging assessment and treatment of probable
high-risk patients during the year of the study. Neither
control practice systematically invited patients, both pre-
ferring to assess patient opportunistically when they
attended for other reasons. One year after the project
began the project nurse was made available to the control
group practices.
Evaluation
One year after CVD risk factor data were first extracted, a
second data extract was undertaken to assess outcomes.
Patients were considered to have been assessed if there
was a record of cardiovascular risk factor status (blood
pressure and cholesterol levels) in their electronic medical
records. They were considered to be eligible for treatment
if their recorded risk factors indicated that they met the
criteria in Table 1. The primary outcome was the number
of eligible patients who were started on treatment from
the list of those identified as probably at high risk of CVD.
Secondary outcomes were the numbers of probable high-
risk patients assessed; the numbers identified as eligible
for treatment; the numbers of eligible patients started on
treatment. We also report the numbers of patients referred
to smoking cessation services, for exercise on prescription
or dietary advice. Statistical analysis was carried out using
EpiInfo 6.0.
Results
The six practices included 1091 patients identified as aged
35 to 74, without a diagnosis of CVD, not taking antihy-
pertensive treatment, but probably at high risk. Of these
patients 30 (2.7%) were excluded because they were
unsuitable to be invited for CVD risk assessment: 25 were
not on the practice list and five were in hospital for more
than six months (Figure 1 and Table 2).BMC Public Health 2008, 8:73 http://www.biomedcentral.com/1471-2458/8/73
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Flow chart of the project evaluation Figure 1
Flow chart of the project evaluation.
Patients registered with 6 practices in Sandwell 
Intervention group: 11,901 patients in four practices
Control group: 8,515 patients in two practices 
Control group  
CVD risk factors assessed and ten-
year CVD risk calculated:  
N = 129 (27.9% of those invited) 
Identified as eligible for:
Aspirin  
N = 89 (19.2% of those invited) 
Antihypertensive  
N = 58 (12.5% of those invited) 
Statin
N = 100 (21.6% of those invited) 
At least one treatment 
N = 100 (21.6% of those invited) 
Intervention group  
CVD risk factors assessed and ten-
year CVD risk calculated:  
N = 370 (61.9% of those invited) 
High risk patients suitable to be invited for CVD risk factor 
assessment.
Intervention group: 598 patients 
Control group: 463 patients 
Identified as eligible for:
Aspirin  
N = 273 (45.7% of those invited) 
Antihypertensive  
N = 170 (28.4% of those invited) 
Statin
N = 293 (49.0% of those invited) 
At least one treatment 
N = 297 (49.7% of those invited) 
Prescribed:
Aspirin  
N = 65 (10.9% of those invited) 
Antihypertensive  
N = 96 (16.1% of those invited) 
Statin
N = 200 (33.4% of those invited) 
At least one treatment 
N = 243 (40.6% of those invited) 
Prescribed:
Aspirin  
N = 9 (1.9% of those invited) 
Antihypertensive  
N = 13 (2.8% of those invited) 
Statin
N = 54 (11.7% of those invited) 
At least one treatment 
N = 59 (12.7% of those invited) 
Patients identified as probably at >20% ten-year CVD risk
Intervention group: 617 patients 
Control group: 474 patients 
30 patients 
excludedBMC Public Health 2008, 8:73 http://www.biomedcentral.com/1471-2458/8/73
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Suitable patients assessed
Of the 1061 patients suitable for CVD risk assessment,
499 (47.0%) were fully assessed during the project, 61.9%
in the intervention group and 27.9% in the control group.
Compared to information only practices, the relative risk
of being assessed was 2.22 (95% CI: 1.89 to 2.60) in inter-
vention group practices (Table 3).
Suitable patients identified as eligible for treatment
In total 397 (37.4%; 95% CI: 34.5% to 40.4%) of patients
suitable for CVD risk assessment were found to be eligible
for at least one drug treatment. Compared to information
only practices, the relative risk of being found to be eligi-
ble for drug treatment in the project nurse practices was
2.30 (95% CI: 1.90 to 2.78).
In the intervention practices more patients the following
proportions of patients eligible for inclusion were identi-
fied as eligible (49.7%) for any preventive treatment,
(45.7%) for aspirin, (28.4%) for antihypertensives and
(49.0%) for statins. In the control practices the equivalent
proportions identified as eligible for treatment were
(21.6%) for any preventive treatment, (19.2%) for aspi-
rin, (12.5%) for antihypertensives and (21.6%) (Table 3).
Probable high-risk patients suitable for CVD risk 
assessment who were started on treatment
In the intervention practices, 40.6% of all high-risk
patients suitable for inclusion in the project were started
on at least one treatment, compared to 12.7% in the infor-
Table 2: Numbers of patients aged 35 to 74, free from CVD and not taking antihypertensive drugs and numbers whose ten-year CVD 
risk* probably exceeds 20%
Practice Practice list Number aged 35–74, free from CVD and not taking 
antihypertensive drugs (percentage of practice list)
Number with ten-year CVD risk* probably 
>20% (percentage of practice list)
PN1 2,029 681 (33.6%) 106 (5.2%)
PN2 2,825 894 (31.6%) 129 (4.6%)
PN3 3,447 1,192 (34.6%) 177 (5.1%)
PN4 3,600 1,149 (31.9%) 205 (5.7%)
All project nurse practices 11,901 3,916 (32.9%) 617 (5.2%)
Info1 4,005 1,371 (34.2%) 182 (4.5%)
Info2 4,510 1,626 (36.1%) 292 (6.5%)
All information only practices 8,515 2,997 (35.2%) 474 (5.6%)
All practices 20,416 6,913 (33.9%) 1,091 (5.3%)
* See text for an explanation of the way in which ten-year CVD risk is calculated
Table 3: Numbers of patients eligible for CVD risk assessment, numbers assessed and numbers identified as eligible for drug 
treatments
Practice Eligible for CVD 
risk assessment*
CVD risk 
calculated (% of 
those eligible for 
assessment)
Identified as 
eligible for aspirin 
(% of those eligible 
for assessment)
Identified as 
eligible for 
antihypertensive 
(% of those eligible 
for assessment)
Identified as 
eligible for statin 
(% of those eligible 
for assessment)
Identified as 
eligible for at least 
one treatment (% 
of those eligible 
for assessment)
PN1 103 60 (58.3%) 40 (38.8%) 22 (21.4%) 43 (41.7%) 44 (42.7%)
PN2 128 m (69.5%) 65 (50.8%) 29 (22.7%) 69 (53.9%) 70 (54.7%)
PN3 164 88 (53.7%) 70 (42.7%) 52 (31.7%) 76 (46.3%) m (46.3%)
PN4 203 133 (65.5%) 98 (48.3%) m (33.0%) 105 (51.7%) 107 (52.7%)
All project nurse 
practices
598 m (61.9%) 273 (45.7%) 170 (28.4%) 293 (49.0%) 297 (49.7%)
Info1 175 75 (42.9%) 51 (29.1%) 36 (20.6%) 57 (32.6%) 57 (32.6%)
Info2 288 54 (18.8%) 38 (13.2%) 22 (7.6%) 43 (14.9%) 43 (14.9%)
All information 
only practices
463 129 (27.9%) 89 (19.2%) 58 (12.5%) 100 (21.6%) 100 (21.6%)
All practices 1061 499 (47.0%) 362 (34.1%) 228 (21.5%) 393 (37.0%) 397 (37.4%)
* In project nurse practices these patients were actively invited. In the information only practices they were seen opportunistically when they 
consulted for other reasons.BMC Public Health 2008, 8:73 http://www.biomedcentral.com/1471-2458/8/73
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mation only practices. This is a relative risk of 3.19 (95%
CI: 2.47 to 4.12).
Proportions of probable high-risk patients referred to 
other services
In the intervention practices more patients were referred
to Sandwell Physical Activity Referral Scheme for advice
on physical activity (6.4% v 0.9%; P < 0.001 by Chi
squared test) and for dietary advice on weight loss (1.5%
v 0.0%; P = 0.006 by Fishers exact test). The proportions
of smokers were referred to smoking cessation services
were not significantly different (18.8% v 15.3%; P < 0.536
by Chi squared test) (Table 4).
Eligible patients started on treatment
Further analysis was carried out in order to determine
whether eligible patients were equally likely to be started
on treatment in intervention and control practices. In
total 302 patients found to be eligible for drug treatment
were started on at least one appropriate treatment: 81.8%
of those eligible in the intervention group and 59.0% of
those eligible in the control group. Compared to informa-
tion only practices, the relative risk of starting an eligible
patient on at least one appropriate treatment in the
project nurse practices was 1.39 (95% CI: 1.17 to 1.65).
In intervention practices eligible patients were signifi-
cantly more likely to be started on aspirin (23.8% v
10.1%. Relative risk 2.35; 95% CI: 1.22 to 4.53), antihy-
pertensives (56.5%; 22.4%. Relative risk 2.52; 95% CI:
1.43 to 4.14) and statins (68.3% v 54.0%. Relative risk
1.26; 95% CI: 1.04 to 1.54) (Table 5).
Discussion
Main finding of this study
Providing practices with information identifying patients
who were probably at greater than 20% ten-year CVD risk
resulted in significant numbers of new patients eligible for
treatment being identified and started on treatment. We
found that the presence of a project nurse in the practices
more than doubled the probability of patients being
assessed and hence more than doubled the number of
patients identified as eligible for treatment. More surpris-
ingly, among patients identified as eligible for treatment,
the presence of a project nurse significantly increased the
probability that eligible patients were prescribed preven-
tive treatments. Overall, the project nurse therefore tre-
bled the chances of being identified as eligible for and
subsequently started on a preventive treatment. There
were also greater numbers of referrals for advice on phys-
ical activity or diet.
There is some further evidence that the opportunistic
strategy does not always result in patients having their risk
factors measured. In the control group practices 73.0%
(95% CI: 62.6% to 81.9%) of patients who saw the GP
twice or more had all their risk factors assessed. By con-
trast, in the intervention practices, all patients who saw
the project nurse twice or more had all their CVD risk fac-
tors assessed.
There is also some further evidence that general practi-
tioners do not always start treatment in patients whose
risk factors are known and who are known to be eligible
for treatment. Among the 1091 untreated patients initially
selected for inclusion in the study, 116 (10.6%: range
1.9% to 30.8% in the six practices) had sufficient risk fac-
tor information to calculate CVD risk (a smoking history,
two blood pressures and a total cholesterol level) already
in their electronic medical records. Hence it was already
possible to determine that they were eligible for treatment
before the project began.
The invitation strategy was clearly superior to opportunis-
tic assessment: a quarter of patients saw their GPs twice or
more but did not have their risk factors assessed. Never-
Table 4: Numbers of patients referred to other services
Practice Referred for advice on physical 
activity (%)*
Referred to dietician (%)* Referred to smoking cessation 
service (% of smokers)
PN1 9 (8.7%) 2 (1.9%) 7 (6.8%)
PN2 10 (7.8%) 1 (0.8%) 13 (10.2%)
PN3 14 (8.5%) 3 (1.8%) 4 (2.4%)
PN4 7 (3.4%) 4 (2.0%) 18 (8.9%)
All project nurse practices 40 (6.7%) 10 (1.7%) 42 (7.0%)
Info1 3 (1.7%) 0 (0.0%) 10 (5.7%)
Info2 1 (0.3%) 0 (0.0%) 1 (0.3%)
All information only practices 4 (0.9%) 0 (0.0%) 11 (2.4%)
All practices 44 (4.1%) 10 (0.9%) 53 (5.0%)
* Percentage of all those suitable for assessment (see Table 3 for denominator)BMC Public Health 2008, 8:73 http://www.biomedcentral.com/1471-2458/8/73
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theless, even with systematic invitation, one third of
patients did not attend. Few patients who were offered
treatment declined it. The weakest link in the process was
GP prescribing. Even with the project nurse present, GPs
did not prescribe antihypertensives to half of eligible
patients or aspirin to four fifths. While the presence of a
project nurse appeared to improve both identification and
prescribing, there is clearly scope for further improve-
ment.
What is already known on this topic?
There are studies of other interventions to improve identi-
fication of patients for CVD prevention in primary care.
Over time, continuous feedback may improve identifica-
tion of patients with CVD [12]. Changes made to primary
care electronic medical records have successfully increased
rates of CVD risk factor assessment [13]. In Scotland the
CARDIA system can identify untreated patients eligible for
CVD prevention and prompts GPs to assess risk factors
and prescribe [14]. However the effectiveness of this sys-
tem on prescribing has not been evaluated.
Electronic reminders have been used in a number of set-
tings to try to change clinician behaviour within the exist-
ing health care system. However results in clinical practice
have been mixed. In a US outpatient clinic setting, elec-
tronic reminders had no effect on the management of
heart disease [15]. Among Italian general practitioners, a
reminder increased prescribing of antiplatelet therapy for
patients at high risk of CVD [16]. Electronic reminders
have been demonstrated to increase vaccination levels
[17-19].
A more sophisticated intervention has extracted data from
general practices and fed this back to practices to help
them target hypertension management [20]. This
achieved some success. Evidence suggests that the effects
of electronic reminders on clinician behaviour are
dependent on organisational factors and other incentives
[21-23].
Some studies report increases in prescribing of preventive
drugs. Searches of electronic medical records have been
used to identify patients with diabetes and increase the
proportions in whom aspirin was prescribed [24]. Com-
plex interventions involving guidelines, audit, prompts
and practitioner education have succeeded in improving
prescribing practice for hypertension [25]. A similar
approach has improved identification and treatment of
atrial fibrillation [26].
What this study adds
Information alone is insufficient to ensure action is taken.
Indeed, in one (information only) practice nearly one
third of untreated high risk patients already had sufficient
risk factor information in electronic medical records to
identify them as eligible for treatment. A prevention strat-
egy is most likely to succeed if a system is in place to
ensure that information is acted upon.
The information only practices in the Sandwell Cardiovas-
cular Prevention Project received an intervention similar
to previous studies: information was provided to try to
change clinician behaviour within the existing primary
health care system. However the project nurse practices
received a somewhat different intervention.
Compared to other approaches to primary prevention the
strategy implemented in these practices was relatively sim-
ple. Make use of information technology to identify
patients. Ensure that it is someone's specific responsibility
to invite identified patients, assess them, determine their
eligibility for treatment and discuss their treatment prefer-
ences. Then present this information to the prescriber.
Effectively this creates a new system for CVD prevention.
Rather than expecting the existing primary care system to
act on information, a separate service was created to
respond to the information. This reflects the experience of
industry that it is not the presence of information technol-
ogy but the way in which it is used, that is critical to its
success [27]. It is of note that despite identifying patients,
assessing them and providing this information to general
practitioners, many patients were not prescribed treat-
ments for which they were eligible. This meant that within
this strategy the greatest deviation from optimum practice
was prescribing. This was also the part of the strategy
which most relied on changing behaviour within the
existing system. There may be wider lessons for making
use of patient data and information technology to
improve to patient care.
Conclusion
There are difficulties interpreting this evaluation. There
may be systematic differences between the practices other
than the presence of the project nurse. However, all four
project nurse practices were consistently better than both
control practices. Aspirin use may be under recorded
because it can be obtained over the counter. Nevertheless
there was clearly higher aspirin use in project nurse prac-
tices. The identification and project nurse strategy may not
generalise to other settings with larger multi-partner prac-
tices. This last question can only be addressed with further
research.
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